CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents.

CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents.
复制标题

CD13 抑制增强化疗药物的细胞毒性作用。

DOI:
10.3389/fphar.2018.01042
复制
发表时间:
2018
影响因子:
5.6
通讯作者:
Wang X
Wang X
中科院分区:
医学2区
文献类型:
--
作者:
Zhang J;Fang C;Qu M;Wu H;Wang X;Zhang H;Ma H;Zhang Z;Huang Y;Shi L;Liang S;Gao Z;Song W;Wang X

文献摘要

参考文献

被引文献

相似文献

肝癌的多药耐药(MDR)是一个严重的问题。虽然CD 13是人肝癌干细胞的生物标志物,但CD 13与MDR的关系尚不清楚。本研究使用肝癌细胞模型来了解CD 13在增强化疗药物的细胞毒效应中的作用。细胞毒性剂可诱导CD 13表达。CD 13抑制剂bestatin可增强细胞毒性药物的抗肿瘤作用。同时,靶向CD 13的siRNA和中和抗体可以增强5-氟尿嘧啶(5-FU)的细胞毒作用。CD 13过表达增加细胞毒性剂处理后的细胞存活,而CD 13的敲低导致细胞对细胞毒性剂处理的超敏反应。从机制上讲,CD 13的抑制导致细胞活性氧(ROS)的增加。BC-02是一种新型的bestatin和5 FU的互作前体药物(杂合药物)。值得注意的是,BC-02可以抑制亲本细胞和耐药细胞的细胞活性,同时显著增加ROS水平。此外,BC-02治疗的荷H22细胞的昆明小鼠的存活时间与最大剂量的卡培他滨治疗相当。这些数据暗示了通过靶向CD 13逆转MDR的治疗方法,并表明BC-02是有效的抗肿瘤化合物。
Multidrug resistance (MDR) of hepatocellular carcinoma is a serious problem. Although CD13 is a biomarker in human liver cancer stem cells, the relationship between CD13 and MDR remains uncertain. This study uses liver cancer cell model to understand the role of CD13 in enhancing the cytotoxic effect of chemotherapy agents. Cytotoxic agents can induce CD13 expression. CD13 inhibitor, bestatin, enhances the antitumor effect of cytotoxic agents. Meanwhile, CD13-targeting siRNA and neutralizing antibody can enhance the cytotoxic effect of 5-fluorouracil (5FU). CD13 overexpression increases cell survival upon cytotoxic agents treatment, while the knockdown of CD13 causes hypersensitivity of cells to cytotoxic agents treatment. Mechanistically, the inhibition of CD13 leads to the increase of cellular reactive oxygen species (ROS). BC-02 is a novel mutual prodrug (hybrid drug) of bestatin and 5FU. Notably, BC-02 can inhibit cellular activity in both parental and drug-resistant cells, accompanied with significantly increased ROS level. Moreover, the survival time of Kunming mice bearing H22 cells under BC-02 treatment is comparable to the capecitabine treatment at maximum dosage. These data implicate a therapeutic method to reverse MDR by targeting CD13, and indicate that BC-02 is a potent antitumor compound.
DOI: 10.1038/nrdp.2016.18
发表时间: 2016-04-14
影响因子: 81.5
作者:
Llovet, Josep M.;Zucman-Rossi, Jessica;Gores, Gregory
通讯作者: Gores, Gregory
BC-02 通过上调 ROS 依赖性 DNA 损伤来根除肝癌干细胞。
DOI: 10.3892/ijo.2017.4159
发表时间: 2017-12-01
影响因子: 5.2
作者:
Dou, Chunhui;Fang, Chunyan;Wang, Xuejian
通讯作者: Wang, Xuejian
DOI: 10.1021/ml3000758
发表时间: 2012-12-01
影响因子: 4.2
作者:
Su, Li;Cao, Jiangying;Xu, Wenfang
通讯作者: Xu, Wenfang
DOI: 10.1038/srep42499
发表时间: 2017-02-13
期刊: Scientific reports
影响因子: 4.6
作者:
Casadei Gardini A;Foca F;Scartozzi M;Silvestris N;Tamburini E;Faloppi L;Brunetti O;Rudnas B;Pisconti S;Valgiusti M;Marisi G;Foschi FG;Ercolani G;Tassinari D;Cascinu S;Frassineti GL
通讯作者: Frassineti GL
DOI: 10.2174/1389450117666151209120831
发表时间: 2016-01-01
影响因子: 3.2
作者:
Mazzoccoli, Gianluigi;Miele, Luca;Vinciguerra, Manlio
通讯作者: Vinciguerra, Manlio